Intarcia Therapeutics anticipates filing for FDA approval at the end of the third quarter of 2016. At this year's ADA presentation, Julio Rosenstock, MD, said the insertion method for the novel ...
DUROS continuous delivery of exenatide resulted in a reduced incidence and persistence of treatment-associated nausea. Nausea rates among patients receiving ITCA 650 at 40 mcg/day were similar to ...
HbA1c lab result The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months. ORLANDO — ITCA 650, an osmotic mini-pump inserted subdermally in ...
Officials say the company will file with FDA some time in the third quarter of 2016 to begin the approval process for the novel delivery system that brings a continuous, microscopic dose of exenatide ...
BOSTON., Intarcia Therapeutics, Inc. today announced top-line results from its more than 4,000 patient Cardiovascular Safety Study (FREEDOM-CVO trial), clearing the last major clinical hurdle in the ...
Patients treated with ITCA 650 60mcg experienced superior reductions in HbA1c versus those treated with Januvia® (sitagliptin) 100mg (-1.5% versus -0.8%; p<0.001) ITCA 650 60mcg produced significantly ...
BOSTON, Oct. 1, 2014 -- Intarcia Therapeutics, Inc. today announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 (exenatide, delivered continuously once or ...
Acquisition of world class peptide team and therapeutic assets complements Intarcia's antibody fragment deal with Numab earlier this year – both targeting diabetes & obesity Phoundry and Numab assets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results